TBPH Q1 2023 Earnings — Theravance Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

TBPHTheravance Biopharma, Inc.

$716M

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$10M-21.1% YoY

Gross Profit

-$4M-39.9% margin

Operating Income

-$25M-239.1% margin

Net Income

-$22M-212.0% margin

EPS (Diluted)

$-0.35

QoQ Revenue Growth

-28.9%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$12M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$539M

Total Liabilities

$168M

Stockholders' Equity

$371M

Cash & Equivalents

$188M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10M	$13M	-21.1%
Gross Profit	-$4M	-$10M	+58.7%
Operating Income	-$25M	-$37M	+33.1%
Net Income	-$22M	-$26M	+14.9%

Revenue Segments

YUPELRI Monotherapy

$16M61%

Viatris collaboration agreement

$10M39%

Collaboration revenue

$6,0000%